From Financial Modeling Prep: 2024-10-21 13:08:20

Cantor Fitzgerald maintains an “Overweight” rating for CVRx, Inc. (NASDAQ: CVRX) at $10.55, focusing on their innovative heart failure therapies like Barostim.

The American Medical Association approved new CPT Category I codes for Barostim therapy, effective January 1, 2026, recognizing its clinical benefits and expanding patient access.

CVRx stock price surged to $10.91, a 14.96% increase, post-AMA approval, indicating investor confidence and active trading interest.

With a market cap of $237.68 million, CVRx’s stock has fluctuated between $9.65 and $11.03, reflecting market response to the company’s growth potential and recent developments.



Read more at Financial Modeling Prep:: CVRx, Inc. (NASDAQ: CVRX) Maintains “Overweight” Rating by Cantor Fitzgerald